ShingrixⓇ: An Overview for Pharmacists
Elizabeth Claus, Paige Hoffman, Vivian Lee
ShingrixⓇ is a recombinant zoster vaccine (RZV) that contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system. This subunit vaccine is approved for the prevention of herpes zoster also known as shingles. A quarter of the population is at risk of developing herpes zoster during their lifetime and two thirds of people with the disease are aged 50 years or older.1 With the rise in adults aged 50 years or older in the United States due to the aging “baby boomer” generation, it is important that health care providers are properly educated and armed with the information that is needed to understand, educate and administer the ShingrixⓇ vaccination for their patients. It is important that healthcare professionals are comfortable navigating the challenges that result from the novelty of a new herpes zoster vaccine in order to ensure that their patients are effectively covered.